Bristol-Myers Squibb stock (US1101221083): China deal worth up to $15.2B

Bristol-Myers Squibb announced a major partnership with China's Jiangsu Hengrui Pharmaceuticals potentially worth $15.2 billion, targeting oncology and immunology assets amid recent Q1 earnings beats.

Bristol-Myers Squibb shares traded around $56.40 on the NYSE as of May 14, 2026, following news of a landmark partnership with China's Jiangsu Hengrui Pharmaceuticals. The deal, valued at up to $15.2 billion, aims to co-develop up to 13 programs in oncology, hematology, and immunology, providing the company broader access to promising assets. This comes after the firm reported first-quarter earnings that beat estimates, according to MarketBeat as of 05/14/2026 and Pluang as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb Company
• Sector/industry: Pharmaceuticals / Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: Oncology, immunology drugs
• Home exchange/listing venue: NYSE (BMY)
• Trading currency: USD

Bristol-Myers Squibb Co: core business model

Bristol-Myers Squibb Co focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company operates in oncology, hematology, immunology, cardiovascular, and neuroscience areas, with a portfolio including blockbuster drugs like Eliquis, Opdivo, and Revlimid. Its business model emphasizes R&D investment, strategic partnerships, and global commercialization to address unmet medical needs.

The firm maintains a market capitalization of approximately $114.68 billion, with an enterprise value of $150.62 billion as reported by Pluang as of 05/14/2026. Bristol-Myers Squibb generates revenue primarily from patented pharmaceuticals sold in the US and international markets.

Main revenue and product drivers for Bristol-Myers Squibb Co

Key products drive revenue, with oncology drugs like Opdivo contributing significantly. The company has shown strong earnings performance, beating expectations for three consecutive quarters. Recent highlights include European approval for Sotyktu, bolstering its immunology portfolio, per Pluang as of 05/14/2026.

First-quarter results exceeded revenue and earnings estimates, supporting operational strength despite some cash flow outflows. The new China partnership expands pipeline access, potentially offsetting patent cliffs on legacy products.

Industry trends and competitive position

In the biopharma sector, Bristol-Myers Squibb competes with peers like Pfizer and Merck through innovation in immuno-oncology. Trends toward personalized medicine and biologics favor its R&D focus. The Hengrui deal positions it strongly in Asia, a key growth market.

Why Bristol-Myers Squibb Co matters for US investors

As a NYSE-listed leader in US healthcare, Bristol-Myers Squibb offers exposure to the $500+ billion US pharma market. Its drugs treat prevalent conditions like cancer, relevant to American demographics and Medicare spending.

Conclusion

Bristol-Myers Squibb Co continues to advance through strategic deals like the $15.2 billion Hengrui partnership and solid Q1 earnings. Shares hover near $56 amid a 52-week range of $42.52-$62.89. Investors track pipeline progress and market execution for US-listed pharma exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.